GE HealthCare's MINItrace™ Magni achieves CE Mark; Copper-64 expands PETtrace™ Solid Target Platform beyond Gallium-68
GE HealthCare announced CE Mark approval for its MINItrace Magni compact, self-shielded cyclotron, aimed at enabling in-house PET radioisotope production with automated, simplified operation. The company also expanded its PETtrace Solid Target Platform beyond Gallium-68 and Zirconium-89 to support Copper-64 production, relevant to copper-based imaging agents and the potential Copper-64/Copper-67 theranostic pair. The developments are product-portfolio milestones in molecular imaging; no financial terms or revenue guidance were disclosed.
Key figures
- Employees
- 54000
- Revenue business scale
- $20.6 billion
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.